Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRCAT-E: Node-Sparing Radiation, Capecitabine, and PD-1/CTLA-4 for MSS Rectal Cancer
NCT07068763Phase 2Recruiting
- Sponsor
- Sir Run-Run Shaw Hospital
- Start
- Oct 2025
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in rectal cancer, sponsored by Sir Run-Run Shaw Hospital. Primary endpoint: Clinical and pathological complete response rate at 12 weeks. Started Oct 2025; status: recruiting.
02
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT07068763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07068763.